Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P00973
UPID:
OAS1_HUMAN
Alternative names:
E18/E16; p46/p42 OAS
Alternative UPACC:
P00973; A8K4N8; F8VXY3; P04820; P29080; P29081; P78485; P78486; Q16700; Q16701; Q1PG42; Q3ZM01; Q53GC5; Q53YA4; Q6A1Z3; Q6IPC6; Q6P7N9; Q96J61
Background:
2'-5'-oligoadenylate synthase 1, known as E18/E16 or p46/p42 OAS, plays a pivotal role in the innate antiviral response. It synthesizes 2'-5'-oligoadenylates (2-5A) that activate RNase L, leading to viral and cellular RNA degradation. This enzyme is crucial for halting viral replication and is involved in apoptosis, cell growth, differentiation, and gene regulation. Its activity against viruses like VSV, HSV-2, and EMCV highlights its broad antiviral spectrum.
Therapeutic significance:
Given its role in Immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia, targeting 2'-5'-oligoadenylate synthase 1 offers a promising avenue for therapeutic intervention. Understanding its function could pave the way for novel treatments for viral infections and immune disorders.